Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amylin Shares Rise As Icahn Raises Stake

By Pharmaceutical Processing | February 6, 2009

NEW YORK (AP) — Shares of Amylin Pharmaceuticals Inc. outpaced the broader market Thursday as billionaire investor Carl Icahn builds on his ownership position in the company as he attempts to replace board members. The San Diego-based company’s stock rose 79 cents, or 6.4 percent, to close at $13.16, outpacing gains made in the broader market. Amylin shares have traded between $5.50 and $35 over the past 52 weeks. Carl Icahn boosted his ownership of the company to 9.43 percent of outstanding stock from about 8.3 percent previously, according to a Securities and Exchange Commission filing. In January, Icahn filed documents with the SEC stating he intended to nominate five people to Amylin’s board of directors. It is similar to the powerplay he made prior to taking control of ImClone Systems Inc. in 2006 and his attempt to take over Biogen Idec Inc. Shortly after his filing, Eastbourne Capital Management, which owns a 12.5 percent stake in Amylin, said it would nominate a slate of five directors. Amylin’s board currently has 12 directors. Amylin has been reeling from falling sales of its diabetes treatment Byetta and shares are down about 59 percent over the past 52 weeks. The drug was linked to cases of acute pancreatitis in 2008, raising concern over the approval of the company’s next-generation diabetes treatment LAR. Byetta is taken twice-daily while LAR would be taken once-weekly. Amylin and Eli Lilly & Co. are partners on the drug along with Alkermes Inc. They will likely face competition from Novo Nordisk, which is developing the once-daily drug liraglutide. Merck & Co. already sells Januvia and Bristol-Myers Squibb Co. and AstraZeneca are developing a treatment called saxagliptin.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE